S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

$2.06
-0.07 (-3.29%)
(As of 03/28/2024 ET)
Today's Range
$2.05
$2.17
50-Day Range
$1.54
$2.13
52-Week Range
$1.07
$2.95
Volume
45,000 shs
Average Volume
113,072 shs
Market Capitalization
$49.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
417.8% Upside
$10.67 Price Target
Short Interest
Healthy
0.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Eledon Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.78) to ($1.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.61 out of 5 stars

Medical Sector

295th out of 938 stocks

Pharmaceutical Preparations Industry

139th out of 438 stocks

ELDN stock logo

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock Price History

ELDN Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals Inc ELDN
Eledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officer
See More Headlines
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/29/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+417.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-87,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.68 per share
Book Value
$6.12 per share

Miscellaneous

Free Float
19,504,000
Market Cap
$49.85 million
Optionable
Optionable
Beta
0.85
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. David-Alexandre C. Gros M.D.Dr. David-Alexandre C. Gros M.D. (Age 52)
    Ph.D., CEO & Non Independent Director
    Comp: $807.96k
  • Dr. Steven N. Perrin Ph.D. (Age 58)
    President, Chief Scientific Officer & Non Independent Director
    Comp: $603.9k
  • Mr. Paul Sean Little (Age 59)
    CFO & Principal Accounting Officer
    Comp: $611.71k
  • Mr. John Herberger
    Vice President of Technical Operations
  • Mr. Bryan E. Smith J.D. (Age 44)
    General Counsel, Corporate Secretary & Chief Compliance Officer
    Comp: $377.14k
  • Dr. David Hovland Ph.D.
    Chief Regulatory Officer
  • Dr. Eliezer Katz F.A.C.S.
    FACS, M.D., Chief Medical Officer

ELDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELDN shares.
View ELDN analyst ratings
or view top-rated stocks.

What is Eledon Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12 month target prices for Eledon Pharmaceuticals' stock. Their ELDN share price targets range from $9.00 to $13.00. On average, they predict the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 417.8% from the stock's current price.
View analysts price targets for ELDN
or view top-rated stocks among Wall Street analysts.

How have ELDN shares performed in 2024?

Eledon Pharmaceuticals' stock was trading at $1.80 at the beginning of the year. Since then, ELDN stock has increased by 14.4% and is now trading at $2.06.
View the best growth stocks for 2024 here
.

Are investors shorting Eledon Pharmaceuticals?

Eledon Pharmaceuticals saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 36,400 shares, a decrease of 6.7% from the February 29th total of 39,000 shares. Based on an average trading volume of 80,200 shares, the days-to-cover ratio is presently 0.5 days.
View Eledon Pharmaceuticals' Short Interest
.

When is Eledon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ELDN earnings forecast
.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) announced its earnings results on Thursday, November, 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.01. During the same quarter in the prior year, the business posted ($3.91) earnings per share.

Who are Eledon Pharmaceuticals' major shareholders?

Eledon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.05%), Vanguard Group Inc. (2.87%), Vanguard Group Inc. (2.87%), Northern Trust Corp (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little.
View institutional ownership trends
.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELDN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners